Premium
Uric acid lowering in relation to HbA1c reductions with the SGLT2 inhibitor tofogliflozin
Author(s) -
Ouchi Motoshi,
Oba Kenzo,
Kaku Kohei,
Suganami Hideki,
Yoshida Akihiro,
Fukunaka Yasunori,
Jutabha Promsuk,
Morita Asuka,
Otani Naoyuki,
Hayashi Keitaro,
Fujita Tomoe,
Suzuki Tatsuya,
Yasutake Masahiro,
Anzai Naohiko
Publication year - 2018
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.13170
Subject(s) - quartile , medicine , uric acid , endocrinology , urinary system , diabetes mellitus , type 2 diabetes mellitus , confidence interval
An integrated analysis was performed with data from 4 phase 2 and phase 3 studies of tofogliflozin in which patients with type 2 diabetes mellitus received the sodium‐glucose cotransporter 2 inhibitor tofogliflozin for up to 24 weeks. Sex differences, baseline haemoglobin A1c (HbA1c) and serum uric acid (UA) levels, and log 10 ‐transformed urinary N‐acetyl‐β‐D‐glucosaminidase ratio were significantly correlated with the reduction in serum UA levels at both 4 and 24 weeks in multivariate analysis (respectively, P < .0001). The decrease in HbA1c levels was greatest in the group with the highest baseline HbA1c level (quartile 4; HbA1c > 8.6%) and lowest in the group with the lowest baseline HbA1c level (quartile 1; HbA1c ≤ 7.4%). The decrease in serum UA levels was greatest in the quartile 1 group and lowest in the quartile 4 group. In most groups, the maximum decrease in serum UA levels was seen in the first 4 weeks, while the maximum decrease in HbA1c was seen at week 24. Thus, serum UA levels were significantly decreased in patients with moderate HbA1c levels.